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ABSTRACT
Introduction: Hypoglycemia is a complication
in the management of type 2 diabetes, and
elderly people are at greater risk of experiencing
hypoglycemia events than younger patients.
Insulin analogs achieve glycemic control with
minimal risk of hypoglycemia and may
therefore be a good treatment option for all
patients.
Methods: A1chieve was an international,
multicenter, prospective, open-label, non-
interventional, 24-week study in people with
type 2 diabetes who started/switched to therapy
with biphasic insulin aspart 30, insulin detemir
or insulin aspart (alone/in combination) in
routine clinical practice. This sub-analysis
evaluated clinical safety and effectiveness of
The A1chieve trial was registered with ClinicalTrials.gov
(NCT00869908).
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insulin aspart as part of a basal-bolus regimen
(±oral glucose-lowering drugs) in three age-
groups (B40,[40–65, and[65 years) of insulin-
experienced and insulin-naive people with type
2 diabetes.
Results: In total, 4,032 patients were included in
the sub-analysis. After 24 weeks of insulin aspart
treatment, significant improvements versus
baseline were observed in all age-groups for:
proportion of people with C1 hypoglycemia
events (18.3–27.1% and 11.0–12.7%, at baseline
and 24 weeks, respectively), C1 major
hypoglycemia events (3.3–6.7% and 0–0.2%),
and C1 nocturnal hypoglycemia events
(9.2–13.7% and 2.9–4.9%); glycated hemoglobin
(9.6–9.8% and 7.4%); fasting plasma glucose
(change from baseline ranged from -3.6 to
-4.4 mmol/l); and post-breakfast post-prandial
plasma glucose (change from baseline ranged
from -5.5 to -5.9 mmol/l). Fourteen serious
adverse drug reactions were reported. Health-
related quality of life was significantly improved
for all age-groups (all, p\0.001).
Conclusion: All age-groups showed improved
glycemic control and reduced risk of
hypoglycemia when starting/switching to
insulin aspart therapy within a basal-bolus
regimen; this may be particularly important
for elderly patients given their greater risk of
hypoglycemia versus younger patients.
Keywords: Elderly; Insulin aspart; Type 2
diabetes
INTRODUCTION
The worldwide prevalence of diabetes was
estimated at 366 million in 2011 (8.3% of the
population), and is predicted to rise to 552
million (9.9%) by 2030 [1]; type 2 diabetes
accounts for approximately 95% of these
cases [2].
Treatment in patients with type 2 diabetes
varies with age; for example, elderly patients
may be more likely than younger patients to
have comorbidities and need polypharmacy,
which, in the case of some drugs, may disrupt
glycemic control, reduce quality of life, and
increase the risk of severe hypoglycemia [3–6].
Furthermore, elderly patients may be unable to
adequately self-monitor blood glucose levels
due to poor dexterity, and cognitive and visual
impairments [7]. The differences between
patient age-groups emphasize the need for
individualized care in these different groups.
With their more favorable clinical profiles
(lower risk of hypoglycemia, flexible dosing,
improved convenience, and greater treatment
satisfaction) compared with human insulin [8,
9], insulin analogs may be a better choice for
starting or optimizing insulin therapy for most
patients, including the elderly [3].
Insulin aspart (NovoRapid; Novo Nordisk
A/S, Bagsvaerd, Denmark) is a rapid-acting
insulin analog that can be administered
immediately before or after a meal [10], and a
large body of evidence supports the clinical
utility of insulin aspart when administered as
part of a basal-bolus regimen [11–17]. In
addition to the data from randomized clinical
trials, observational studies have demonstrated
that basal-bolus regimens are effective in
everyday practice in type 1 and type 2 diabetes
[18–20]. There is a lack of specific clinical
studies in different age-groups to elucidate the
risks and benefits of existing treatments in older
compared with younger patients, and therefore,
large observational studies can be invaluable for
providing data from this cohort of patients.
A1chieve was an international non-
interventional study that was conducted to
examine the safety and effectiveness of
initiating or switching to insulin analogs
(alone/in combination with other anti-diabetes
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medication) as part of routine clinical care
among patients with type 2 diabetes [18]. In
this sub-group analysis of the A1chieve study,
we aimed to investigate the safety and
effectiveness of insulin aspart administered at
mealtime(s) as required, together with basal
insulin (insulin detemir, neutral protamine
Hagedorn or insulin glargine) with or without
oral glucose-lowering drugs (OGLDs) in three
age-groups (B40, [40–65 and [65 years of age)
with type 2 diabetes.
MATERIALS AND METHODS
All local requirements for Health Authorities or
Ethics Committee approvals were obtained, if
applicable. In every country, participants signed
informed consent forms and were free to
withdraw from the study at any time. The
study was conducted in accordance with the
Declaration of Helsinki of 1964, as revised in
2008 [21] and the Guidelines for Good
Pharmacoepidemiology Practice [22].
Study Design
This was a sub-analysis of a 24-week,
international, prospective, multicenter, non-
interventional, observational study, which was
conducted in 28 countries encompassing seven
geographical regions: China, South Asia
(Bangladesh, India, Pakistan), East Asia
(Indonesia, Korea, Malaysia, Philippines,
Singapore, Taiwan), North Africa (Algeria,
Morocco, Tunisia, Libya), Middle East (Egypt,
Iran, Jordan, Turkey, Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, United Arab Emirates,
Yemen), Latin America (Argentina, Mexico),
and Russia [18].
In the A1chieve study, the safety and
effectiveness of initiating or switching to
treatment with insulin analogs (alone/in
combination with other anti-diabetes
medication) was evaluated in patients with
type 2 diabetes receiving routine clinical care
between January 2009 and June 2010. Choice of
insulin analog and the insulin dose were based
on the clinical judgment of the treating
physician, and with patient agreement. Insulin
analogs (all manufactured by Novo Nordisk A/S,
Bagsvaerd, Denmark) were used in accordance
with the label approved by the regulatory
authority. Further details, inclusion and
exclusion criteria, and study design have been
reported elsewhere [18].
This sub-analysis included patients starting
or switching to treatment with insulin aspart
administered at mealtime(s) plus basal insulin
(insulin detemir, neutral protamine Hagedorn,
or insulin glargine) with or without OGLDs. As
the basal component of the regimen could be
human insulin or an insulin analog, basal
insulin dose is expressed as U (or IU). The
decision to prescribe OGLDs, stop OGLDs, or
switch the type of OGLDs prescribed during the
study was made by the treating physician.
Assessments
Assessments were at baseline (time when the
treating physician prescribed insulin aspart as
part of a basal-bolus regimen), approximately
12 weeks after baseline (results not reported
here), and study end (approximately 24 weeks
after baseline).
The primary endpoint was the incidence of
serious adverse drug reactions (SADRs),
including major hypoglycemia events. Other
safety assessments included the change in the
number of hypoglycemia events between
baseline and 24 weeks. These were based on
patient recall of events within the last 4 weeks
of the pre-scheduled clinical visit. A
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hypoglycemia event was defined as an event
with one of the following characteristics:
symptoms of hypoglycemia that resolved with
oral carbohydrate intake, glucagon or
intravenous glucose; or symptomatic or
asymptomatic plasma glucose \3.1 mmol/l.
Major hypoglycemia events were defined as
hypoglycemia events with severe central
nervous system symptoms consistent with
hypoglycemia, in which the patient was
unable to treat himself/herself. Nocturnal
hypoglycemia events were defined as
individualized symptomatic events consistent
with hypoglycemia, that occurred while the
patient was asleep, between bedtime after the
evening insulin injection and before getting up
in the morning [before morning determination
of fasting plasma glucose (FPG) and before
morning injection, if relevant].
The effectiveness of therapy was determined
from measurements made by the treating
physician team at each assessment visit; data
were collected from the physicians’ clinical
notes, and participants’ recall and self-
monitoring diary/meter, as available.
Effectiveness outcomes encompassed change
from baseline after 24 weeks in blood glucose
control measures [glycated hemoglobin (HbA1c;
most recent during the preceding 4 weeks), FPG
(pre-breakfast), and post-prandial plasma
glucose (PPG; 90 to 120 min after the
beginning of breakfast)], body weight, and
health-related quality of life (HRQoL). HRQoL
was measured by self-report at baseline and after
24 weeks using the EQ-5D questionnaire [23],
which evaluates five domains of patient health/
lifestyle (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression).
Scores in these five domains were converted to
a single utility value (UK VAS set), with ‘1.00’
indicating ‘full health’ and ‘0.00’ indicating the
state ‘deceased’ [24, 25].
Due to the observational nature of the study
and lack of protocol enforcement to report all
effectiveness outcomes, results are reported here
as per available reports.
Statistical Analyses
Analyses were performed in all patients with a
baseline visit and who were treated with insulin
aspart as part of a basal-bolus regimen at baseline.
For those patients who withdrew from the study,
data collected until the date of withdrawal was
used for analysis. Sub-group analyses were
conducted according to age (B40, [40–65 and
[65 years), and pre-study insulin experience
(insulin-experienced and insulin-naive).
The sample size (full cohort) was based on the
number of people (20,000) exposed for 6 months
required to confirm at 95% confidence a
frequency of any one adverse drug reaction of
C15 events/100,000 person-years. This would
detect a rate of major hypoglycemia as reported
in any published clinical trial.
Changes from baseline in efficacy measures
were evaluated using Student’s paired t test. For
hypoglycemia, the percentage of patients
reporting at least one event was analyzed
using McNemar’s test. All statistical analyses
were two-sided, using a pre-specified 5%
significance level, and were performed by
Novo Nordisk using SAS Version 9.1.3 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Study Participants
Data for 4,032 people (6% of the total A1chieve
population) with type 2 diabetes who received
insulin aspart as part of a basal-bolus regimen
were collected: 571 patients aged B40 years, 2,801
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patients aged[40–65 years, and 660 patients aged
[65 years (Table 1). Most patients (61.3%)
starting basal-bolus regimens were previously
treated with other insulin regimens (Table 1).
Previous insulin therapies included human
soluble insulin, neutral protamine Hagedorn,
premixed human insulin, insulin glargine, and
others, such as premixed insulin lispro.
Physicians cited the need to improve
glycemic control (92.9–95.1% in the three age-
groups) as the most frequent reason for
prescribing insulin aspart as part of a basal-
bolus regimen. Between 30.5% and 39.6% of
physicians gave patient dissatisfaction with
current therapy, need to reduce the risk of
hypoglycemia and need to reduce plasma
glucose variability as reasons for initiating or
switching to insulin aspart therapy. There was
no obvious difference in these reasons between
age-groups.
Study Treatments and Dose
Mean (standard deviation; SD) basal insulin
dose started at 0.31 (0.18) U (or IU)/kg and
increased slightly to 0.36 (0.20) U (or IU)/kg
after 24 weeks in the B40 years age-group.
Similar increases from starting dose were
observed in the [40–65 years age-group [0.31
(0.16) U (or IU)/kg at baseline and 0.37 (0.19) U
(or IU)/kg after 24 weeks] and the[65 years age-
group [0.29 (0.16) U (or IU)/kg at baseline and
0.36 (0.20) U (or IU)/kg after 24 weeks]. The
mean starting basal insulin dose and the basal
insulin dose after 24 weeks was higher in
insulin-experienced patients [0.39–0.41 U (or
IU)/kg in the three age-groups after 24 weeks]
than in insulin-naive patients [0.26–0.32 U (or
IU)/kg in the three age-groups after 24 weeks].
Mean (SD) bolus insulin dose increased
slightly from baseline to 24 weeks in all age-
Table 1 Baseline patient and disease characteristics by age-group
Baseline variable Age-group
£40 years >40–65 years >65 years
N 571 2,801 660
Insulin status, n
Insulin-naive 211 1,106 244
Insulin-experienced 360 1,695 416
Gender (male/female), %a 56.6/43.4 55.1/44.9 47.5/52.5
Mean (SD) age, years 30.3 (8.7) 53.3 (6.5) 71.8 (5.2)
Mean (SD) body weight, kgb 71.9 (17.5) 79.5 (17.7) 72.3 (14.6)
Mean (SD) BMI, kg/m2 c 25.7 (5.4) 28.9 (6.1) 27.2 (5.1)
Mean (SD) age at diagnosis, yearsd 25.9 (8.7) 43.7 (7.6) 57.3 (9.5)
Mean (SD) diabetes duration, yearsd 5.2 (4.9) 9.6 (6.2) 14.5 (8.8)
Due to the observational nature of the study, data were not collected or not recorded for some patients
BMI body-mass index
a n = 2,799, n = 659 for the[40–65 and[65 years age-groups, respectively
b n = 549, n = 2,700, n = 635 for the B40,[40–65 and[65 years age-groups, respectively
c n = 517, n = 2,621, n = 612 for the B40,[40–65 and[65 years age-groups, respectively
d n = 552, n = 2,785, n = 657 for the B40,[40–65 and[65 years age-groups, respectively
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groups [B40 years age-group: 0.42 (0.22) U/kg to
0.48 (0.26) U/kg; [40–65 years age-group: 0.37
(0.19) U/kg to 0.42 (0.21) U/kg; [65 years age-
group: 0.38 (0.21) U/kg to 0.43 (0.22) U/kg]. The
mean starting bolus insulin dose and the bolus
insulin dose after 24 weeks was higher in
insulin-experienced patients (0.43–0.50 U/kg
in the three age-groups after 24 weeks) than in
insulin-naive patients (0.39–0.44 U/kg in the
three age-groups after 24 weeks).
The number of concomitant OGLDs used
was generally reduced as patients entered the
study and remained stable or reduced slightly
during the course of the 24 weeks of insulin
aspart therapy as part of a basal-bolus regimen
(Fig. 1); there was no major difference in OGLD
use between the age-groups. A similar pattern
was observed in insulin-naive and insulin-
experienced patients, but a greater proportion
of insulin-naive patients than insulin-
experienced patients were on two or more
OGLDs at baseline. However, after 24 weeks of
insulin aspart therapy as part of a basal-bolus
regimen, the proportion of patients using two
or more OGLDs was very similar in the insulin-
naive and insulin-experienced groups, in all
age-groups.
Metformin and/or sulfonylureas were the
predominant OGLDs in all age-groups at study
initiation and after 24 weeks of treatment with
insulin aspart; [70% of patients in all age-
groups were prescribed metformin after
24 weeks.
SADRs
Of the 4,032 people with type 2 diabetes who
received insulin aspart as part of a basal-bolus
regimen, there were 14 reports of SADRs:
five hypoglycemia episodes in the B40 years
Fig. 1 Oral glucose-lowering drug use among patients
starting or switching to a basal-bolus insulin regimen with
insulin aspart in the A1chieve study. n = 264 pre-study,
n = 194 at baseline and n = 204 at 24 weeks in B40 years
age-group. n = 2,062 pre-study, n = 1,479 at baseline and
n = 1,467 at 24 weeks in[40–65 years age-group. n = 440
pre-study and n = 270 at baseline and 24 weeks in[65 years
age-group. OGLD oral glucose-lowering drug
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age-group; five in the [40–65 years age-group,
including two hypoglycemia episodes, one
report of diabetic ketoacidosis, one report of a
fall, and one report of a pelvic fracture; and four
in the [65 years age-group, including two
hypoglycemia episodes, one report of
inadequate diabetes control, and one episode
of hypoglycemia unconsciousness. All SADRs
occurred in insulin-experienced patients.
Eleven of these events were probably related to
treatment (with good reasons and sufficient
documentation to assume a causal relationship)
and three were possibly related (a causal
relationship was conceivable and could not be
dismissed).
Hypoglycemia
In each age-group (in the entire cohort), there
was a significant reduction from baseline in
overall hypoglycemia, major hypoglycemia,
and nocturnal hypoglycemia after 24 weeks of
treatment with insulin aspart as part of a basal-
bolus regimen (Table 2). There were no reports
of major hypoglycemia at 24 weeks in the
[40–65 years age-group and [65 years age-
group (Table 2).
Rates of hypoglycemia, major hypoglycemia
and nocturnal hypoglycemia were numerically
higher at baseline among insulin-experienced
than insulin-naive patients (Table 2). Rates of
hypoglycemia and nocturnal hypoglycemia
were significantly reduced in all three age-
groups of insulin-experienced patients after
24 weeks of treatment with insulin aspart as
part of a basal-bolus regimen (Table 2). Across
all age-groups, the proportion of insulin-
experienced patients reporting at least one
hypoglycemia event was 24.3–40.3% at
baseline versus 11.2–14.1% at 24 weeks, and at
least one nocturnal hypoglycemia event was
13.9–20.6% at baseline versus 3.0–6.7% at
24 weeks. There were no reports of major
hypoglycemia events at 24 weeks in the
[40–65 and [65 years age-groups, and
significant reductions in the proportion of
patients reporting major hypoglycemia events
between baseline and 24 weeks in the B40 years
age-group.
There was a significant increase from
baseline to 24 weeks in the proportion of
insulin-naive patients reporting at least one
hypoglycemia event, except in the [65 years
age-group (4.7%, 4.9% and 8.2% of patients at
baseline compared with 10.2%, 8.1% and 10.6%
of patients at 24 weeks in the B40, [40–65, and
[65 years age-groups, respectively; Table 2).
However, rates of nocturnal hypoglycemia did
not significantly increase with insulin aspart
treatment in insulin-naive patients of any age-
group, and there were no reports of major
hypoglycemia at 24 weeks (Table 2).
The proportion of patients taking
sulfonylureas who reported hypoglycemia
events at baseline was 9.6% (n = 115), 11.7%
(n = 1,109), and 15.1% (n = 232) in the
B40 years age-group, [40–65 years age-group,
and [65 years age-group, respectively. At
24 weeks, there was no significant change
from baseline in the proportion of patients
reporting hypoglycemia events: 3.6% (n = 28),
7.1% (n = 254) and 4.7% (n = 43), respectively.
Glucose Control
Baseline HbA1c levels were high in all age-
groups in insulin-naive and insulin-
experienced patients (Fig. 2). Mean (SD)
change in HbA1c between baseline and week
24 in insulin-experienced patients was -2.0%
(2.0%) in the B40 years age-group, -2.0%
(1.6%) in the [40–65 years age-group, and
-1.8% (1.9%) in the [65 years age-group.
Mean (SD) change in HbA1c between baseline
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and week 24 in insulin-naive patients was
-3.1% (2.1%) in the B40 years age-group,
-2.8% (2.0%) in the [40–65 years age-group,
and -2.8% (2.1%) in the [65 years age-group
(Fig. 2).
The proportion of patients (insulin-
naive plus insulin-experienced) with HbA1c
\7.0% at baseline was similar between age-
groups at baseline (3.5–6.9%) and at 24 weeks
(32.8–35.9%). A greater proportion of patients
appeared to achieve HbA1c \7.0% following
24 weeks of treatment with insulin aspart as
part of a basal-bolus regimen than at baseline
(Table 3). In the [65 years age-group, 12.0%
and 14.3% of patients had baseline HbA1c
\7.5% in the insulin-naive and insulin-
experienced cohorts, respectively. Following
24 weeks of treatment with insulin aspart as
part of a basal-bolus regimen, 63.0% and 55.0%
patients aged [65 years achieved HbA1c \7.5%.
Baseline FPG was high in all age-groups in
insulin-naive and insulin-experienced patients,
and significantly improved in all age-groups
after 24 weeks treatment with insulin aspart as
part of a basal-bolus regimen (Table 3). Baseline
FPG values were higher in insulin-naive
than insulin-experienced patients, and
improvements were numerically greater in
insulin-naive patients than in insulin-
experienced patients (Table 3). Furthermore,
baseline FPG was slightly higher at younger
ages, and the reductions after 24 weeks were
Table 2 Hypoglycemia at baseline, and after 24 weeks of treatment with insulin aspart as part of a basal-bolus regimen
Measurement % patients with at least one event (event/person-year)
Age £40 years Age >40–65 years Age >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Hypoglycemia (overall)
Entire cohort 27.1 (12.3) 12.7*** (4.1) 18.6 (8.8) 11.1*** (3.6) 18.3 (10.3) 11.0*** (3.4)
n 571 474 2,801 2,532 660 582
Insulin-experienced 40.3 (19.0) 14.1*** (5.2) 27.6 (13.6) 13.1*** (4.0) 24.3 (14.7) 11.2*** (3.3)
n 360 298 1,695 1,528 416 366
Insulin-naive 4.7 (0.8) 10.2* (2.4) 4.9 (1.6) 8.1** (3.0) 8.2 (2.9) 10.6 (3.5)
n 211 176 1,106 1,004 244 216
Hypoglycemia (major)a
Entire cohort 6.7 (1.5) 0.2*** (0.0) 3.6 (0.9) 0*** (0) 3.3 (0.6) 0*** (0)
Insulin-experienced 10.3 (2.4) 0.3*** (0.0) 5.8 (1.4) 0*** (0) 4.1 (0.8) 0*** (0)
Insulin-naive 0.5 (0.1) 0 (0) 0.4 (0.2) 0* (0) 2.0 (0.3) 0* (0)
Hypoglycemia (nocturnal)a
Entire cohort 13.7 (3.8) 4.9*** (1.1) 9.2 (2.6) 4.1*** (0.7) 9.8 (3.5) 2.9*** (0.6)
Insulin-experienced 20.6 (5.8) 6.7*** (1.6) 14.2 (4.1) 5.2*** (0.9) 13.9 (5.3) 3.0*** (0.6)
Insulin-naive 1.9 (0.3) 1.7 (0.2) 1.5 (0.4) 2.4 (0.4) 2.9 (0.5) 2.8 (0.6)
* p\0.05 vs. baseline; ** p\0.01 vs. baseline; *** p\0.001 vs. baseline
a n for each cohort same as for hypoglycemia (overall) data
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correspondingly greater in the younger age-
group (Table 3). Likewise, baseline post-
breakfast PPG was high in all age-groups and
higher in insulin-naive than insulin-
experienced patients (Table 3). After 24 weeks
treatment with insulin aspart as part of a basal-
bolus regimen, statistically significant
improvements in PPG were observed in all
sub-groups and these were greater in insulin-
naive groups than insulin-experienced groups
(Table 3).
Body Weight
Baseline body weight was higher in the
[40–65 years age-group than the other two age-
groups (Table 3). Weight remained stable after
24 weeks treatment with insulin aspart as part of a
basal-bolus regimen in the B40 and [65 years
age-groups, but there was a significant weight loss
in patients aged [40–65 years (Table 3). In
insulin-experienced patients, there was a
significant weight increase in the B40 years age-
group, a significant weight loss in the
[40–65 years age-group, and no significant
change in weight in the [65 years age-group
(Table 3). By contrast, weight remained stable
after 24 weeks treatment with insulin aspart as
part of a basal-bolus regimen in all age-groups in
the insulin-naive cohort (Table 3).
Health-Related Quality of Life
Statistically significant improvement in UK VAS
scores after 24 weeks were observed in all age-
groups except insulin-naive patients in the
Fig. 2 Mean plasma glycated hemoglobin among patients
starting or switching to a basal-bolus insulin regimen with
insulin aspart in the A1chieve study. Entire cohort: n = 383
in B40 years age-group; n = 2,117 in [40–65 years age-
group; n = 452 in[65 years age-group. Insulin-experienced
cohort: n = 249 in B40 years age-group; n = 1,306 in
[40–65 years age-group; n = 289 in[65 years age-group.
Insulin-naive cohort: n = 134 in B40 years age-group;
n = 811 in[40–65 years age-group; n = 163 in[65 years
age-group. HbA1c glycated hemoglobin. ***p\0.001 vs.
baseline
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B40 years age-group (Table 3). This younger
age-group had considerably higher UK VAS
scores (i.e., better HRQoL) at baseline than the
older age-groups, regardless of previous therapy.
DISCUSSION
Insulin aspart, administered at mealtime(s) as part
of a basal-bolus regimen, was associated with
significant improvements in glycemic control in
patients with type 2 diabetes across a wide age
spectrum in this sub-analysis of the observational
A1chieve study. These improvements in glycemic
control were achieved despite a reduction in the
number of concomitant OGLDs used. Older age
and basal-bolus insulin therapy were identified as
significant predictors of response to insulin
therapy (defined as HbA1c \7.5% and/or [1%
HbA1c reduction 12 months post-insulin
initiation) at 1 year in a recent UK retrospective
study [26]; this current analysis shows good
response in everyday practice across the range of
patient ages.
The cohort of patients aged [65 years who
were recruited in this non-interventional study
experienced lower rates of hypoglycemia at
baseline than patients aged B40 years, and
similar rates to those aged [40–65 years.
Patients in the insulin-experienced B40 years
age-group had particularly high rates of
hypoglycemia, nocturnal hypoglycemia and
major hypoglycemia at baseline. However, the
proportion of patients reporting hypoglycemia
episodes decreased on the basal-bolus regimen
with insulin aspart in all age-groups, and great
reassurance can be drawn from the very low
rates of major hypoglycemia after 24 weeks.
Furthermore, sulfonylurea use did not appear to
increase the rate of hypoglycemia in any age-
group; indeed improvements in hypoglycemia
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17.3% of patients in all age-groups receiving
sulfonylureas at 24 weeks. While guidelines
recommend discontinuation of sulfonylureas
on commencement of more complex insulin
regimens (such as basal-bolus insulin regimens)
in order to minimize the risk of hypoglycemia
episodes, this does not always occur in practice
[27]. The beneficial effect of insulin aspart as
part of a basal-bolus regimen on hypoglycemia
may therefore reflect the overall reduction in
polypharmacy.
Elderly patients are at greater risk of
hypoglycemia events than patients of a
younger age [3]. This, together with the
association of hypoglycemia with the use of
basal-bolus therapy, may have raised concerns
over the application of this regimen in elderly
patients. However, the results from this study
showed that elderly patients in both the entire
cohort and the insulin-experienced cohort had
lower rates of hypoglycemia following 24 weeks
of a basal-bolus regimen with insulin aspart
versus baseline. Indeed, the rate in the oldest
age-group was similar to the younger age-
groups after 24 weeks of treatment (in both
insulin-experienced and insulin-naive
populations).
Consistent with earlier reports [5, 6], quality
of life was lower at baseline for older patients
versus the youngest age-group. However,
elderly patients experienced the greatest
magnitude of changes in HRQoL following
24 weeks of basal-bolus therapy with insulin
aspart. It is likely that the significant
improvements in quality of life reflect the
observed improvements in glycemic control
and benefits on hypoglycemia risk [28, 29],
but may also reflect other factors, such as
reduction in OGLD use or the flexible
treatment regimen offered by insulin aspart.
The limitations of this observational study
design have been discussed elsewhere [18], and
include: the lack of randomization and absence
of a control arm, the absence of control for
concomitant medication, dietary or lifestyle
changes, and lack of data relating to the
progress of disease-related complications (e.g.,
diabetic nephropathy). Some variables (e.g.,
hypoglycemia events) were also based on
participant recall and the incidence, especially
of minor events, could be under-estimated.
Despite the limitation with reporting of
hypoglycemia episodes, the improvement in
glycemic control across all age-groups after
24 weeks of basal-bolus therapy (reduction in
HbA1c levels between 1.8% and 3.1%), coupled
with the modest rates of hypoglycemia
reported by patients, suggest that insulin
aspart as part of a basal-bolus regimen is an
effective and tolerable treatment that can
reduce risk for hypoglycemia events. Further,
most randomized controlled trials exclude
elderly patients with diabetes through
imposed age limitations, or stringent
exclusion criteria. Therefore, the sub-group of
elderly patients from this large observational
study will provide valuable information
regarding the use of basal-bolus regimens in
elderly patients.
This international study offered the
opportunity to view results from a regional
perspective. However, the smaller number of
patients in the oldest and youngest age-groups
receiving insulin aspart as part of a basal-bolus
regimen would make interpretation of
individual region results problematic. The
overall proportion of participants in A1chieve
that received the basal-bolus regimen was low
[18] despite poor general glycemic control and
the obvious need for more intensive insulin
regimens. This may highlight a general
reluctance among physicians to adopt an
intensive regimen, such as a basal-bolus
regimen, or limited awareness of the potential
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benefits in use of insulin analogs in less
developed countries.
In conclusion, insulin aspart administered
within a basal-bolus regimen as part of routine
clinical practice had efficacy and good
tolerability in all age-groups as either a
starting insulin regimen, or when patients
were switched from other regimens. The
results also show that the use of insulin aspart
as part of a basal-bolus regimen is effective and
tolerable in elderly people with diabetes,
although treatment should be individualized.
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